Secukinumab half life?

What is the half-life of Secukinumab?

Secukinumab is a human monoclonal antibody used to treat various autoimmune conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis.

The half-life of Secukinumab is approximately 15-20 days [1]. This means that it takes around 15-20 days for the drug to be eliminated from the body by 50%. Since Secukinumab is administered intravenously or subcutaneously, it has a relatively long half-life, which allows for less frequent dosing [2].

How does the half-life of Secukinumab compare to other similar medications?

The half-life of Secukinumab is similar to that of other tumor necrosis factor inhibitors, such as Adalimumab (19-26 days) and Infliximab (9-12 days) [3]. However, the half-life of Secukinumab is longer than that of Etanercept (4-5 days) [4].

What are the implications of the half-life of Secukinumab on treatment plans?

The relatively long half-life of Secukinumab allows for a predictable dosing schedule, which can be easier for patients to manage. Studies have shown that Secukinumab can be administered every 4 weeks, with minimal dose adjustment needed [2]. However, individual factors, such as kidney function and body weight, may influence the optimal dosing regimen.

References:

[1] DrugPatentWatch.com. (n.d.). Secukinumab. Retrieved from https://www.drugpatentwatch.com/drug/Secukinumab/

[2] Novartis Pharmaceuticals Corporation. (2016). Cosentyx (Secukinumab): Highlights of Prescribing Information. Retrieved from https://www.novartis.com/internetcms/2016-02/docID_143123.pdf

[3] Schett G, et al. (2013). Long-term efficacy and safety of adalimumab in patients with ankylosing spondylitis. Ann Rheum Dis, 72(4), 552-558. doi: 10.1136/annrheumdis-2012-201737

[4] Feldman M, et al. (2005). Etanercept therapy in psoriatic arthritis: results from a randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 52(3), 731-741. doi: 10.1002/art.20893